NewAmsterdam Pharma (NAMS) reported Wednesday that its full-year 2024 net loss widened to $241.6 million from a net loss of $176.9 million a year earlier.
Analysts polled by FactSet expected a loss of $194.5 million.
Revenue for full-year 2024 was $45.6 million up from $14.1 million a year earlier.
Analysts surveyed by FactSet expected $33.8 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments